• Wenrong An, Yanqin Huang, Shouqiang Chen, Tao Teng, Juan Liu, and Yunsheng Xu.
• First College of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
• Medicine (Baltimore). 2021 Oct 22; 100 (42): e27569e27569.

BackgroundDiabetic nephropathy (DN) is 1 of the most serious complications of diabetes mellitus and the leading cause of end-stage renal disease in the world. Huangkui capsule, extracted from Abelmoschus manihot (L.) medic (AM), has been widely used to treat DN. However, there is no consensus on the efficacy of Huangkui capsule for DN. This study aims to perform meta-analysis to systematically review the efficacy and safety of Huangkui capsule.MethodsThe following 9 electronic databases will be comprehensively searched: PubMed, web of science, MEDLINE, Embase, Cochrane Library, China National Knowledge Infrastructure, Chinese Scientific Journals Database, Wanfang data, and Chinese BioMedicine Literature Database. The retrieval time is from their inception to May 2021. According to the inclusion and exclusion criteria, 2 reviewers independently completed the study selection, data extraction, risk of bias assessment, and data synthesis. Review Manager Version 5.3 software will be used to conduct meta-analysis.ResultsThis study provides a high-quality synthesis to assess the efficacy of Huangkui capsule for treating diabetic nephropathy.ConclusionThe result of this systematic review will provide objective evidence-based basis to judge the effectiveness and safety of Huangkui capsule on diabetic nephropathy.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

17 keywords...

hide…